AbbVie's SWOT analysis: stock outlook amid Humira erosion and pipeline growth
AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...
AbbVie retains Humira market share above 70%: report
AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic ...
centerforbiosimilars9d
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...
AbbVie's Stock Is Unfairly Cheap
The company's immunology portfolio, led by Skyrizi and Rinvoq, continues to thrive despite Humira's patent expiration, ...
The Motley Fool17d
3 High-Yield Dividend Stocks to Buy Now and Hold at Least a Decade
Its former lead drug is an anti-inflammatory injection called Humira. At recent prices, AbbVie stock offers a 3.7% yield. The company has more than quadrupled its dividend payout since spinning ...
Mint26d
Mint Primer: Why are docs in the dock over a ‘work trip’?
This week, the department of pharmaceuticals (DoP) said the Indian arm of US firm AbbVie violated the newly amended Uniform Code for Pharmaceutical Marketing Practices. What did AbbVie do, and ...
The Motley Fool29d
2 Excellent Dividend Stocks to Buy on the Dip
AbbVie and Amgen experienced sell-offs after unimpressive phase 2 data. Both companies continue to record strong financial results and have exciting pipelines. Both have grown their dividends at a ...